All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-06-06T12:01:41.000Z

EHA2023 abstracts: What's hot in multiple myeloma and other plasma cell dyscrasias?

Jun 6, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

Bookmark this article

To help navigate the exciting content being presented at the EHA2023 Congress, the Multiple Myeloma Hub Steering Committee have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.

Top abstracts in multiple myeloma and other plasma cell dyscrasias

S100

First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma

Hermann Einsele

S190

First results from the REDIRECTT-1 study with teclistamab (TEC) + talquetamab (TAL) simultaneously targeting BCAM and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Maria-Victoria Mateos 

S192

Talquetamab (TAL) + daratumumab (DARA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results

Nizar J Bahlis

S195

Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KARMMA-3 analysis in high-risk subgroups

Krina Patel

S197

LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma

Hans C Lee

S199

A phase 3, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma (DREAMM-3)

Meletios Dimopoulos

S202

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

Nikhil Munshi

S203

Quadruplet induction therapy, ASCT and MRD-modulated consolidation and treatment cessation in newly diagnosed multiple myeloma: Final analysis of the MASTER trial

Luciano Costa

S204

Safety and tolerability of CAEL-101, an anti-amyloid monoclonal antibody, combined with anti-plasma cell dyscrasia therapy in patients with light-chain amyloidosis: 18-month results of a phase 2 study

Jason Valent

P870

Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MAGNETISMM studies

Salomon Manier

Top abstracts by region

In addition to the top abstracts selected by our steering committee, the Multiple Myeloma Hub would like to highlight some key region-specific abstracts in the field of multiple myeloma and plasma cell dyscrasias.

Latin America

Asia Pacific

Middle East and Africa

Europe

 

EHA 2023 top abstracts

To download this document, click below.

Download here

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox